Alexandra M. Stevens

Author

Also Known As

A Stevens, A. M. Stevens, A. Stevens, Alexandra M Stevens, Alexandra M. Stevens, Alexandra McLean Stevens, Alexandra Stevens, Stevens, Alexandra M.

Publications

697

Citations

H-Index

Concepts

All Affiliations

Baylor College of Medicine Children's Cancer Center Texas Children's Hospital The University of Texas MD Anderson Cancer Center Rice University

About

Alexandra M. Stevens is an author at Baylor College of Medicine specializing in medicine, cancer cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	92
2	Cell Biology	2	2	71
3	Natural Sciences	1	1	13
4	Public Health	1	1	11
5	Biochemistry	1	1	58

Alexandra M. Stevens

Publications

406

Citations

H-Index

Page 1

	Year	Citations
Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance Alexandra M. Stevens, Jennifer Miller, Jaime O. Munoz, Blood Advances	2017	80
Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation Alexandra M. Stevens, Michael Xiang, Lisa N. Heppler, Blood Advances Chemoprevention StrategyLipid PeroxidationApoptosisImmunologyCell Death	2019	58
Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia Pınar Ataca Atilla, Mary K. McKenna, Haruko Tashiro, Journal for ImmunoTherapy of Cancer	2020	57
Rhodium(II) Proximity‐Labeling Identifies a Novel Target Site on STAT3 for Inhibitors with Potent Anti‐Leukemia Activity Matthew B. Minus, Wei Liu, Farrukh Vohidov, Angewandte Chemie International Edition	2015	37
Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience Adriana Trabal, Amber Gibson, Jiasen He, Cancers	2023	31
Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated Alexandra M. Stevens, Eric S. Schafer, Minhua Li, Cancers	2023	18
Real‐world experience in treating pediatric relapsed/refractory or therapy‐related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium Eric S. Schafer, Karen Chao, Alexandra M. Stevens, Pediatric Blood & Cancer	2022	16
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia Sara Silbert, Alexander W. Rankin, Chloe Hoang, Blood	2025	16
Levofloxacin prophylaxis for pediatric leukemia patients: Longitudinal follow‐up for impact on health care‐associated infections Andrea L. Davis, Alexandra M. Stevens, Julienne Brackett, Pediatric Blood & Cancer	2022	14
Targeting STAT3 anti-apoptosis pathways with organic and hybrid organic–inorganic inhibitors Matthew B. Minus, Haopei Wang, Jaime O. Munoz, Organic & Biomolecular Chemistry	2020	13

Page 1